ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?

Chang and Yew discuss the ATS/CDC/ERS/IDSA clinical practice guidelines for treatment of drug-resistant tuberculosis. The ATS/CDC/ERS/IDSA have recommended the use of linezolid and bedaquiline to treat all patients with multidrug-resistant TB (MDR-TB), regardless of the drug-susceptibility testing r...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2020-09, Vol.202 (5), p.777-778
Main Authors: Chang, Kwok-Chiu, Yew, Wing-Wai
Format: Article
Language:English
Subjects:
Antibiotics
Antitubercular Agents - therapeutic use
Best practice
Centers for Disease Control and Prevention, U.S
Clinical practice guidelines
Correspondence
Drug delivery systems
Drug resistance
Drug therapy
Humans
Meta-analysis
Multidrug resistant organisms
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chang and Yew discuss the ATS/CDC/ERS/IDSA clinical practice guidelines for treatment of drug-resistant tuberculosis. The ATS/CDC/ERS/IDSA have recommended the use of linezolid and bedaquiline to treat all patients with multidrug-resistant TB (MDR-TB), regardless of the drug-susceptibility testing results. Although the present guidelines have substantiated the role of linezolid and bedaquiline in the treatment of fluoroquinolone-resistant MDR-TB, the IPD meta-analysis findings might have been overextrapolated, with findings regarding the use of linezolid and bedaquiline for the management of fluoroquinolone-resistant MDR-TB applied to fluoroquinolone-susceptible MDR-TB. Retrospective analysis of linezolid in better-defined cohorts with MDR-TB have suggested that linezolid would be useful largely in the treatment of more complicated MDR-TB.
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201912-2460LE